Promising natural products targeting protein tyrosine phosphatase SHP2 for cancer therapy

被引:1
作者
Lu, Jiani [1 ]
Yu, Danmei [1 ]
Li, Hongtao [1 ]
Qin, Pengcheng [1 ,2 ]
Chen, Hongzhuan [1 ]
Chen, Lili [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai Frontiers Sci Ctr TCM Chem Biol, Shanghai, Peoples R China
[2] Henan Univ, Sch Pharm, Kaifeng, Peoples R China
基金
上海市自然科学基金;
关键词
cancer therapy; natural products; SHP2; inhibitors; GENOTYPE-PHENOTYPE CORRELATION; PTPN11; MUTATIONS; LEOPARD-SYNDROME; NOONAN-SYNDROME; INHIBITORS; IDENTIFICATION; RESISTANCE; LEUKEMIA; GROWTH; PHOSPHORYLATION;
D O I
10.1002/ptr.8185
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The development of Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors is a hot spot in the research and development of antitumor drugs, which may induce immunomodulatory effects in the tumor microenvironment and participate in anti-tumor immune responses. To date, several SHP2 inhibitors have made remarkable progress and entered clinical trials for the treatment of patients with advanced solid tumors. Multiple compounds derived from natural products have been proved to influence tumor cell proliferation, apoptosis, migration and other cellular functions, modulate cell cycle and immune cell activation by regulating the function of SHP2 and its mutants. However, there is a paucity of information about their diversity, biochemistry, and therapeutic potential of targeting SHP2 in tumors. This review will provide the structure, classification, inhibitory activities, experimental models, and antitumor effects of the natural products. Notably, this review summarizes recent advance in the efficacy and pharmacological mechanism of natural products targeting SHP2 in inhibiting the various signaling pathways that regulate different cancers and thus pave the way for further development of anticancer drugs targeting SHP2.
引用
收藏
页码:1735 / 1757
页数:23
相关论文
共 112 条
  • [1] Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer
    Achkova, Daniela
    Maher, John
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2016, 44 : 333 - 341
  • [2] Protein Tyrosine Phosphatase SHP2 Controls Interleukin-8 Expression in Breast Cancer Cells
    Amante, Romain J.
    Maur, Priska Auf Der
    Richina, Veronica
    Sethi, Atul
    Iesmantavicius, Vytautas
    Bonenfant, Debora
    Aceto, Nicola
    Bentires-Alj, Mohamed
    [J]. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2022, 27 (02) : 145 - 153
  • [3] Natural products in drug discovery: advances and opportunities
    Atanasov, Atanas G.
    Zotchev, Sergey B.
    Dirsch, Verena M.
    Supuran, Claudiu T.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (03) : 200 - 216
  • [4] Discovery and resupply of pharmacologically active plant-derived natural products: A review
    Atanasov, Atanas G.
    Waltenberger, Birgit
    Pferschy-Wenzig, Eva-Maria
    Linder, Thomas
    Wawrosch, Christoph
    Uhrin, Pavel
    Temml, Veronika
    Wang, Limei
    Schwaiger, Stefan
    Heiss, Elke H.
    Rollinger, Judith M.
    Schuster, Daniela
    Breuss, Johannes M.
    Bochkov, Valery
    Mihovilovic, Marko D.
    Kopp, Brigitte
    Bauer, Rudolf
    Dirsch, Verena M.
    Stuppner, Hermann
    [J]. BIOTECHNOLOGY ADVANCES, 2015, 33 (08) : 1582 - 1614
  • [5] Biosynthesis, evolution and ecology of microbial terpenoids
    Avalos, Mariana
    Garbeva, Paolina
    Vader, Lisa
    van Wezel, Gilles P.
    Dickschat, Jeroen S.
    Ulanova, Dana
    [J]. NATURAL PRODUCT REPORTS, 2022, 39 (02) : 249 - 272
  • [6] PROTEIN-TYROSINE-PHOSPHATASE SHPTP2 COUPLES PLATELET-DERIVED GROWTH-FACTOR RECEPTOR-BETA TO RAS
    BENNETT, AM
    TANG, TL
    SUGIMOTO, S
    WALSH, CT
    NEEL, BG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (15) : 7335 - 7339
  • [7] Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
    Bentires-Alj, M
    Paez, JG
    David, FS
    Keilhack, H
    Halmos, B
    Naoki, K
    Maris, JM
    Richardson, A
    Bardelli, A
    Sugarbaker, DJ
    Richards, WG
    Du, JY
    Girard, L
    Minna, JD
    Loh, ML
    Fisher, DE
    Velculescu, VE
    Vogelstein, B
    Meyerson, M
    Sellers, WR
    Neel, BG
    [J]. CANCER RESEARCH, 2004, 64 (24) : 8816 - 8820
  • [8] Understanding the tumor immune microenvironment (TIME) for effective therapy
    Binnewies, Mikhail
    Roberts, Edward W.
    Kersten, Kelly
    Chan, Vincent
    Fearon, Douglas F.
    Merad, Miriam
    Coussens, Lisa M.
    Gabrilovich, Dmitry I.
    Ostrand-Rosenberg, Suzanne
    Hedrick, Catherine C.
    Vonderheide, Robert H.
    Pittet, Mikael J.
    Jain, Rakesh K.
    Zou, Weiping
    Howcroft, T. Kevin
    Woodhouse, Elisa C.
    Weinberg, Robert A.
    Krummel, Matthew F.
    [J]. NATURE MEDICINE, 2018, 24 (05) : 541 - 550
  • [9] Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer
    Bollu, Lakshmi Reddy
    Mazumdar, Abhijit
    Savage, Michelle I.
    Brown, Powel H.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2136 - 2142
  • [10] Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.
    Brana, Irene
    Shapiro, Geoffrey
    Johnson, Melissa Lynne
    Yu, Helena Alexandra
    Robbrecht, Debbie
    Tan, Daniel Shao-Weng
    Siu, Lillian L.
    Minami, Hironobu
    Steeghs, Neeltje
    Hengelage, Thomas
    Tan, Eugene
    Biette, Kelly
    Xu, Kun
    Moody, Susan Elizabeth
    Jove, Maria
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)